Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests

In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable...

Descripción completa

Detalles Bibliográficos
Autores principales: Saponaro, Mariarosaria, Annunziata, Luigi, Turla, Antonella, Viganò, Ilaria, De Laurentiis, Michele, Giuliano, Mario, Del Mastro, Lucia, Montemurro, Filippo, Puglisi, Fabio, De Angelis, Carmine, Buono, Giuseppe, Schettini, Francesco, Arpino, Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656848/
https://www.ncbi.nlm.nih.gov/pubmed/36362392
http://dx.doi.org/10.3390/ijms232113604
Descripción
Sumario:In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice.

Ejemplares similares